Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Age
18–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
≥18 years at the time of enrollment.
Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.
Life expectancy ≥6 months.
Histologically or cytologically confirmed metastatic (stage IV) driver gene-negative non-squamous non-small cell lung cancer (NSCLC) that is unresectable and not amenable to curative therapy
Subjects with no prior systemic chemotherapy for metastatic non-small cell lung cancer (NSCLC).
You may not be if
Presence of any gastrointestinal absorption-impairing conditions (e.g., dysphagia, malabsorption, prior gastrectomy, or uncontrolled vomiting); current use of tube feeding/parenteral nutrition; or existence of anorexia nervosa, psychiatric disorder-induced anorexia, or pain-related feeding intolerance.
Driver gene-positive NSCLC or histologically/cytologically confirmed squamous cell-dominant NSCLC.
Patients with Cushing's syndrome, adrenal/pituitary insufficiency; poorly controlled diabetes mellitus.
Concurrent enrollment in another clinical trial, unless it is an observational/non-interventional study or the follow-up phase of an interventional trial.
Clareo Health | Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis
